This transcript has been edited for clarity.
Jay H. Shubrook, DO: Hi. I'm Jay Shubrook, a family physician and diabetologist at Touro University California in Vallejo. Today we're going to discuss the brand-new 2019 American Diabetes Association (ADA) Abridged Standards for Primary Care[1] and specifically talk about the hyperglycemic guidelines, which include some important changes for primary care. With me is Dr Neil Skolnik, a professor of family and community medicine at the Sidney Kimmel Medical College, Thomas Jefferson University, in Philadelphia, Pennsylvania. Neil, we're happy to have you with us today.
Neil Skolnik, MD: It is a pleasure to be here.
Shubrook: The guidelines came out in January 2019 with important changes, especially for primary care. Today we're going to talk about that first injectable medication for type 2 diabetes. When I think about a first injectable, I just assume that the person's diabetes is out of control and they go on insulin. Tell me more about how this has changed.
Skolnik: That's what a lot of people assume. But these new guidelines are making suggestions for large changes in the way we practice. These are immensely credible, major guidelines[1,2]that come jointly from the ADA and the European Association for the Study of Diabetes (EASD).
